Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

Videos

PlayESC 2021 Inclisiran in polyvascular disease

ESC 2021 Inclisiran in polyvascular disease

Polyvascular disease is a severe manifestation of atherosclerotic cardiovascular disease and an independent predictor of increased risk of cardiovascular events. Prof Derick Raal (University of the Witwatersrand, Johannesburg, South Africa) discusses findings from post hoc analyses from the ORION-9, -10 and -11 trials with the…

read more »
PlayHuygens: Does PCSK9 inhibition impact the vulnerable plaque?

Huygens: Does PCSK9 inhibition impact the vulnerable plaque?

The HUYGENS study (High-Resolution Assessment of Coronary Plaques in a Global Evolocumab Randomized Study NCT03570697) investigated the impact of PCSK9 inhibition on the vulnerable plaque. Results were reported at ESC Congress 2021 (Virtual). Professor Stephen Nicholls, Monash University, Melbourne, Australia discusses the background to the…

read more »
PlayLDL cholesterol lowering and effects on plaque: what can we learn from INTENSITY-HIGH?

LDL cholesterol lowering and effects on plaque: what can we learn from INTENSITY-HIGH?

INTENSITY-HIGH: Investigating the Lowest Threshold of Vascular Benefits from LDL Cholesterol Lowering with a PCSK9 mAb Inhibitor (Alirocumab) in Patients with Stable Cardiovascular Disease The landmark PCSK9 inhibitor trials – FOURIER and ODYSSEY OUTCOMES – established the cardiovascular benefits of lowering LDL cholesterol to very…

read more »
PlayWhy should clinical practice move to an intensive LDL-C lowering approach?

Why should clinical practice move to an intensive LDL-C lowering approach?

Professor Chris Packard discusses the need for this change in the light of the 2019 ESC/EAS dyslipidaemia guidelines.

read more »
PlayHow do clinicians translate intensive LDL-C lowering to their practice?

How do clinicians translate intensive LDL-C lowering to their practice?

Professor Chris Packard discusses the highest-risk-highest benefit strategy.

read more »
PlayAre very low lipoprotein(a) levels safe? Insights from the Copenhagen General Population Study

Are very low lipoprotein(a) levels safe? Insights from the Copenhagen General Population Study

High lipoprotein(a) levels are clearly established as a risk factor for cardiovascular disease and aortic valve stenosis (1,2). Recent lipid guidelines have affirmed the importance of measuring lipoprotein(a) [Lp(a)] in individuals with intermediate risk or with a family or personal history of premature or recurrent…

read more »
PlayWhich lipid markers best identify residual risk in statin-treated patients?

Which lipid markers best identify residual risk in statin-treated patients?

LDL cholesterol is undoubtedly the priority lipid target to prevent atherosclerotic cardiovascular disease. Yet even with attainment of very low levels, high risk patients continue to experience cardiovascular events. The question is: which is the best lipid to target this residual risk? The options include…

read more »
PlayVery low lipoprotein(a) and very low LDL cholesterol – are they safe?

Very low lipoprotein(a) and very low LDL cholesterol – are they safe?

High lipoprotein(a) [Lp(a] is a cardiovascular risk factor. With the development of novel therapies for lowering elevated Lp(a), a key concern is whether very low levels pose any risk. A similar debate has engendered with LDL cholesterol. Professor Chris Packard, University of Glasgow, UK puts…

read more »
PlayVIDEO: GPs in FH care

VIDEO: GPs in FH care

read more »
PlayVIDEO: New FH guidance for Australasia

VIDEO: New FH guidance for Australasia

read more »
PlayVIDEO: The SAMSON Study

VIDEO: The SAMSON Study

read more »
PlayVIDEO: Prof Steve Nicholls discusses STRENGTH

VIDEO: Prof Steve Nicholls discusses STRENGTH

News from AHA 2020 Virtual: Professor Steve Nicholls (Monash University, Melbourne, Australia) puts the STRENGTH results in context

read more »
PlayVIDEO: Prof Steve Nicholls fish oils and AF

VIDEO: Prof Steve Nicholls fish oils and AF

News from AHA 2020 Virtual: Professor Steve Nicholls (Monash University, Melbourne, Australia) discusses fish oils and risk for atrial fibrillation and implications for clinical practice

read more »
PlayProfessor Santos discusses HAUSER-RCT

Professor Santos discusses HAUSER-RCT

read more »
PlayVIDEO: Prof PG Steg Targeting PCSK9 inhibition

VIDEO: Prof PG Steg Targeting PCSK9 inhibition

read more »